METHDILAZINE Drug Patent Profile
✉ Email this page to a colleague
When do Methdilazine patents expire, and what generic alternatives are available?
Methdilazine is a drug marketed by Alpharma Us Pharms and is included in one NDA.
The generic ingredient in METHDILAZINE is methdilazine hydrochloride. There are four drug master file entries for this compound. Additional details are available on the methdilazine hydrochloride profile page.
Summary for METHDILAZINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METHDILAZINE at DailyMed |
US Patents and Regulatory Information for METHDILAZINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpharma Us Pharms | METHDILAZINE HYDROCHLORIDE | methdilazine hydrochloride | SYRUP;ORAL | 087122-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |